Scarica l'app Stockscreener
5.75
2.50%
0.14
Dopo l'orario di chiusura:
5.73
-0.02
-0.35%
Protara Therapeutics Inc Borsa (TARA) Ultime notizie
Revenue per share of Protara Therapeutics, Inc. – DUS:1KPA - TradingView — Track All Markets
Is Protara Therapeutics Inc. stock overvalued by current metricsMarket Movers & Free Expert Verified Stock Movement Alerts - ulpravda.ru
Protara Therapeutics completes $75 million stock offering - MSN
Can Protara Therapeutics Inc. stock attract ESG capital inflows2025 Volatility Report & Free Expert Approved Momentum Trade Ideas - ulpravda.ru
Why Protara Therapeutics Inc. stock is popular among millennialsJuly 2025 Closing Moves & Weekly Market Pulse Updates - ulpravda.ru
Why Protara Therapeutics Inc. stock could see breakout soonPortfolio Profit Report & AI Enhanced Trading Signals - ulpravda.ru
How strong is Protara Therapeutics Inc. stock revenue growthJuly 2025 Review & Expert Curated Trade Setups - ulpravda.ru
Sectors Review: Why Protara Therapeutics Inc. stock is recommended by analystsMarket Activity Summary & Fast Gaining Stock Strategy Reports - ulpravda.ru
Should I hold or sell Protara Therapeutics Inc. stock in 2025Analyst Downgrade & Risk Adjusted Buy and Sell Alerts - ulpravda.ru
Is Protara Therapeutics Inc. stock in correction or buying zoneBull Run & Weekly Watchlist for Hot Stocks - ulpravda.ru
Why Protara Therapeutics Inc. stock is recommended by analysts2025 Price Action Summary & Technical Pattern Alert System - ulpravda.ru
Protara, Ceribell rise on FDA breakthrough designations - MSN
Protara begins patient dosing in phase 3 trial for IV choline therapy - Investing.com Nigeria
Protara Therapeutics (TARA) Begins Phase 3 THRIVE-3 Trial for Ke - GuruFocus
TARA Stock Initiated with 'Overweight' Rating by Piper Sandler | - GuruFocus
Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support - The Manila Times
Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Trial tests first IV choline therapy for patients on long-term IV nutrition - Stock Titan
Why analysts recommend Protara Therapeutics Inc. (1KPA) stock2026 world cup usa national team semifinals young talents counter attacking expert forecast statistical analysis - ulpravda.ru
Why Protara Therapeutics Inc. stock could outperform in 20252026 world cup usa national team quarterfinals young talents high defensive line tactical prediction insights - ulpravda.ru
FDA grants breakthrough therapy designation to Protara’s LM treatment By Investing.com - Investing.com Nigeria
Protara Therapeutics slumps 12%, raises $75M equity at $5.75 per share - MSN
Movement Recap: How strong is Protara Therapeutics Inc stock revenue growthJuly 2025 PostEarnings & Long-Term Capital Growth Strategies - moha.gov.vn
Protara Therapeutics updates on TARA-002 development - The Pharma Letter
Protara, CeriBell rise on FDA breakthrough designations (TARA:NASDAQ) - Seeking Alpha
Protara Therapeutics (TARA) Gains FDA Designations for TARA-002 - GuruFocus
FDA grants breakthrough therapy designation to Protara’s LM treatment - Investing.com
Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations - The Manila Times
Protara Therapeutics Receives Both FDA Breakthrough Therapy - GlobeNewswire
Protara Therapeutics’ TARA-002 Study: A Potential Game-Changer for Lymphatic Malformations - MSN
Levels Update: How forex fluctuations impact Protara Therapeutics Inc 1KPA stock2025 Historical Comparison & Fast Entry and Exit Trade Plans - moha.gov.vn
Assenagon Asset Management S.A. Invests $1.34 Million in Protara Therapeutics, Inc. $TARA - Defense World
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025 - Sahm
Sentiment Watch: Can Protara Therapeutics Inc stock attract ESG capital inflows2025 EndofYear Setup & Weekly High Potential Stock Alerts - moha.gov.vn
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Resistance Check: Is Protara Therapeutics Inc. (1KPA) stock attractive for dividend growth2025 Technical Patterns & Fast Entry Momentum Trade Alerts - moha.gov.vn
Protara Therapeutics raises $86.3 million in offering - MSN
Protara Therapeutics Raises $86.3 Million in Offering - TipRanks
Protara Therapeutics, Inc. (NASDAQ: TARA) details $86.3M equity raise from stock sale - Stock Titan
What analysts say about Protara Therapeutics Inc stockSwing Trading Ideas & Get Alerts Before Market Turns Ugly - earlytimes.in
Acorn Capital Advisors LLC Acquires 472,315 Shares of Protara Therapeutics, Inc. $TARA - MarketBeat
Protara Therapeutics, Inc. $TARA is Velan Capital Investment Management LP's 4th Largest Position - MarketBeat
Protara Announces Closing of $75 Million Public Offering - The Manila Times
Protara announces proposed public offering - MSN
Protara Therapeutics Completes $75 Million Stock Offering - TipRanks
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):